This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.
Wall Street is convinced that anti-obesity GLP-1 drugs constitute a thematic bull case, with Goldman Sachs recently pegging its estimate of annual global sales of these drugs at $130 billion by 2030. In fact, financial analysts have already begun to downgrade the long-term demand outlook for fast food giants such as McDonald's, based on assumptions that 7 percent of the total population in the US would be using GLP-1 drugs in the next 10 years, with the average caloric consumption of those users declining by around 20 percent. Yet, it is the exorbitant price tags of these drugs - at $1,000 or above - that is currently acting as the biggest drag on this unbridled bullish case.
The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, the hormone raises the level of insulin, which decreases blood glucose levels. Simultaneously, it reduces the speed at which the stomach empties its contents into the small intestine, thereby increasing the feeling of fullness and satiation. While initially billed as a treatment for diabetes, many of the drugs that utilize GLP-1 agonists are now sold as a dedicated anti-obesity palliative option, including Novo Nordisk's Wegovy and Eli Lilly and Company's Zepbound.
Just 1 Percent Of ACA Marketplace Plans Currently Cover Novo Nordisk's Anti-Obesity GLP-1 Drug Wegovy, While 0 Percent Do So For Eli Lilly And Company's Zepbound Label
As per a 2021 survey by the CDC, 41.9 percent of the adults in the US aged 20 and above were obese. What's more, study after study has shown that Americans in the lower income strata are much more susceptible to obesity than their higher income counterparts. Yet, it is these underprivileged individuals who are in most need of a viable anti-obesity treatment that are currently being denied coverage under the Affordable Care Act (ACA) marketplace plans.
For the benefit of those who might not be aware, the ACA established exchanges (marketplaces) for healthcare plans where individuals who do not have access to employer-sponsored healthcare coverage can compare various plans from private insurance providers.
As per a recent survey by KFF, Novo Nordisk's Wegovy GLP-1 anti-obesity drug is currently covered by just 1 percent of ACA marketplace plans. In contrast, the company's diabetes-geared Ozempic offering, which leverages the same Semaglutide GLP-1 agonist, is covered by a whopping 82 percent of these marketplace plans.
Interestingly, even when the GLP-1 anti-obesity drugs are covered by these private insurance plans, they are almost always paired with prior authorization requirements.
What are your thoughts on pharmaceutical anti-obesity interventions, including GLP-1 drugs? Do you think this is a viable method for controlling the obesity pandemic, especially as those who are overweight often lack the will to undergo a strict diet-control and exercise regimen? Let us know your opinion in the comments section below.
About the author: Writing is my one incontrovertible passion. Over the past six years, he has authored over 2,200 distinct articles on financial and tech-related topics, spanning nearly 1 million words. And he has been a member of Wcctech mobile team since 2025. As an alumnus of the University of Toronto, Rotman Commerce Program, I bring nuance, in-depth knowledge, and a unique perspective to every topic that I cover. When I'm not writing, I'm traveling the world, exploring hidden confectionaries and restaurants as an aspiring food connoisseur.
Follow Wccftech on Google to get more of our news coverage in your feeds.
